Journal of PeriAnesthesia Nursing
Volume 21, Issue 6 , Pages 385-397 , December 2006

Pharmacological Prophylaxis and Management of Adult Postoperative/Postdischarge Nausea and Vomiting

  • Julie Golembiewski, PharmD

      Affiliations

    • Corresponding Author InformationAddress correspondence to Julie Golembiewski, PharmD, Department of Pharmacy Practice (MC 886), University of Illinois at Chicago College of Pharmacy, 833 S Wood Street, Room 164, Chicago, IL 60612-7230
    • ,
  • Sheri Tokumaru, PharmD

References 

  1. Koivuranta M, Läärä E, Snåre L, et al. A survey of postoperative nausea and vomiting. Anaesthesia. 1997;52:443–449
  2. Apfel C, Läärä E, Koivuranta M, et al. A simplified risk score for predicting postoperative nausea and vomiting. Anesthesiology. 1999;91:693–700
  3. Apfel CC, Kranke P, Katz MH, et al. Volatile anesthetics may be the cause of early but not delayed postoperative vomiting: A randomized controlled trial of factorial design. Br J Anaesth. 2002;88:659–668
  4. Tramèr MR. A rational approach to the control of postoperative nausea and vomiting: Evidence from systematic reviews (Part 1. Efficacy and harm of antiemetic interventions, and methodological issues). Acta Anaesthesiol Scand. 2001;45:4–13
  5. Kovac AL. Prevention and treatment of postoperative nausea and vomiting. Drugs. 2000;59:213–243
  6. ASHP Commission on Therapeutics. ASHP therapeutics guidelines on the pharmacologic management of nausea and vomiting in adult pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm. 1999;56:729–764
  7. Ockner RK. Introduction to gastrointestinal disease. In:  Bennett JC,  Plum F editor. Cecil Textbook of Medicine. 20th ed. Philadelphia, PA: WB Saunders Co; 1996;p. 627–630
  8. Watcha MF, White PF. Postoperative nausea and vomiting. Anesthesiology. 1992;77:162–184
  9. American Gastroenterological Association. AGA technical review on nausea and vomiting. Gastroenterology. 2001;120:263–286
  10. Bailey PL, Egan TD, Stanley TH. Intravenous opioid anesthetics. In:  Miller RD editors. Anesthesia. 5th ed. Philadelphia, PA: Churchill Livingstone; 2000;p. 273–376
  11. Saito R, Takano Y, Kamiya HO. Roles of substance P and NK(1) receptor in the brainstem in the development of emesis. J Pharmacol Sci. 2003;91:87–94
  12. Hornby PJ. Central neurocircuitry associated with emesis. Am J Med. 2001;111:106S–112S
  13. Fortney JT, Gan TJ, Graczyk S, et al. A comparison of the efficacy, safety, and patient satisfaction of ondansetron versus droperidol as antiemetics for elective outpatient surgical procedures. Anesth Analg. 1998;86:731–738
  14. Henzi I, Sonderegger J, Tramèr MR. Efficacy, dose-response, and adverse effects of droperidol for prevention of postoperative nausea and vomiting. Can J Anesth. 2000;47:537–551
  15. Wallenborn J, Gelbrich G, Bulst D, et al. Prevention of postoperative nausea and vomiting by metoclopramide combined with dexamethasone: Randomised double blind multicentre trial. BMJ. 2006;333:324
  16. Henzi I, Walder B, Tramèr MR. Metoclopramide in the prevention of postoperative nausea and vomiting: A quantitative systematic review of randomized, placebo-controlled studies. Br J Anaesth. 1999;83:761–771
  17. Tramèr MR, Reynolds DJ, Moore RA, et al. Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: A quantitative systematic review of randomized placebo-controlled trials. Anesthesiology. 1997;87:1277–1289
  18. Mikawa K, Takao Y, Nishina K, et al. Optimal dose of granisetron for prophylaxis against postoperative emesis after gynecological surgery. Anesth Analg. 1997;85:652–656
  19. Apfel CC, Kortilla K, Abdalla M, et al. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N Engl J Med. 2004;350:2441–2451
  20. Food and Drug Administration. Important drug warning letter from Akorn Pharmaceuticals. 2006;Available at: http://www.fda.gov/medwatch/safety/2001/inapsine.htm. Accessed August 19
  21. White PF, Song D, Abroa J, et al. Effect of low-dose droperidol on the QT interval during and after general anesthesia. Anesthesiology. 2005;102:1101–1105
  22. Perrault LP, Denault AY, Carrier M, et al. Torsades de pointes secondary to intravenous haloperidol after coronary bypass grafting surgery. Can J Anaesth. 2000;47:251–254
  23. Domino KB, Anderson EA, Polissar NL. Comparative efficacy and safety of ondansetron, droperidol, and metoclopramide for preventing postoperative nausea and vomiting: A meta-analysis. Anesth Analg. 1999;88:1370–1379
  24. Holesha W, Dziura-Murauski J. Extrapyramidal side effects of metoclopramide in outpatient surgical patients. J Post Anesth Nurs. 1994;9:107–110
  25. Chen JJ, Frame DG, White TJ. Efficacy of ondansetron and prochlorperazine for the prevention of postoperative nausea and vomiting after total hip replacement or total knee replacement procedures. Arch Intern Med. 1998;158:2124–2128
  26. Khalil S, Philbrook L, Rabb M, et al. Ondansetron/promethazine combination or promethazine alone reduces nausea and vomiting after middle ear surgery. J Clin Anesth. 1999;11:596–600
  27. Altman DF. Drugs used in gastrointestinal diseases. In:  Katzung BG editors. Basic and Clinical Pharmacology. 8th ed. New York: McGraw-Hill; 2001;p. 1064–1076
  28. Kranke P, Morin AM, Roewer N, et al. Dimenhydrinate for prophylaxis of postoperative nausea and vomiting: A meta-analysis of randomized controlled trials. Acta Anaesthesiol Scand. 2002;46:238–244
  29. Clissold SP, Heel RC. Transdermal hyoscine (scopolamine): A preliminary review of its pharamacodynamic properties and therapeutic efficacy. Drugs. 1985;29:189–207
  30. Wang ET, Zhou DR, He LH. Histaminergic response to coriolis stimulation: Implication for transdermal scopolamine therapy of motion sickness. Aviat Space Environ Med. 1992;63:579–582
  31. Takeda N, Morita M, Horii A, et al. Neural mechanisms of motion sickness. J Med Invest. 2001;48:44–59
  32. Harris SN, Sevarino FB, Sinatra RS, et al. Nausea prophylaxis using transdermal scopolamine in the setting of patient-controlled analgesia. Obst Gynecol. 1991;78:673–677
  33. Ferris FD, Kerr IG, Sone M, et al. Transdermal scopolamine use in the control of narcotic-induced nausea. J Pain Symptom Manag. 1991;6:389–393
  34. Kranke P, Morin AM, Roewer N, et al. The efficacy and safety of transdermal scopolamine for the prevention of postoperative nausea and vomiting: A quantitative systematic review. Anesth Analg. 2002;95:133–143
  35. Novartis. Prescribing information: Transderm Scop (transdermal scopolamine). Novartis Consumer Health, Inc. Available at: http://www.transdermscop.com/infomed_prescribing.htm. Accessed August 27, 2006
  36. Figueredo ED, Canosa LG. Ondansetron in the prophylaxis of postoperative vomiting: A meta-analysis. J Clin Anesth. 1998;10:211–221
  37. Philip BK, McLeskey CH, Chelly JE, et al. Pooled analysis of three large clinical trials to determine the optimal dose of dolasetron mesylate needed to prevent postoperative nausea and vomiting. J Clin Anesth. 2000;12:1–8
  38. Roche Pharmaceuticals. Kytril package insert. Nutley, NJ: Roche Pharmaceuticals; 2005;
  39. Tang J, D’Angelo R, White PF, et al. The efficacy of RS-25259, a long-acting selective 5-HT3 receptor antagonist, for preventing postoperative nausea and vomiting after hysterectomy procedures. Anesth Analg. 1998;87:462–467
  40. Gan TJ. Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: Are they all the same?. 2005;19:225–238
  41. Kuryshev YA, Brown AM, Wang L, et al. Interactions of the 5-hydroxytryptamine3 antagonist class of antiemetic drugs with human cardiac ion channels. J Pharmacol Exp Ther. 2000;295:614–620
  42. Navari RM, Koeller JM. Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists. Ann Pharmacother. 2003;37:1276–1286
  43. Harris AL. Cytotoxic-therapy-induced vomiting is mediated via enkephalin pathways. Lancet. 1982;1:714–716
  44. Henzi I, Walder B, Tramèr MR. Dexamethasone for the prevention of postoperative nausea and vomiting: A quantitative systematic review. Anesth Analg. 2000;90:186–194
  45. Merck. Decadron package insert. Whitehouse Station, NJ: Merck & Co., Inc; 2004;
  46. Bleiberg H. A new class of antiemetics: The NK-1 receptor antagonists. Curr Opin Oncol. 2000;12:284–288
  47. Gan TJ, Apfel C, Kovac A. The NK1 receptor antagonist aprepitant for prevention of postoperative nausea and vomiting. American Society of Anesthesiologists Meeting; 2005;Abstract A769. October 24
  48. Merck. Emend package insert. Whitehouse Station, NJ: Merck & Co., Inc; 2006;
  49. Smith I, White PF, Nathanson M, et al. Propofol (An update on its clinical use). Anesthesiology. 1994;81:1005–1043
  50. Tramèr MR, Moore A, McQuay HJ. Propofol anaesthesia and postoperative nausea and vomiting: Quantitative systematic review of randomized studies. Br J Anaesth. 1997;78:247–255
  51. Borgeat A, Ekatodramis G, Schenker CA. Postoperative nausea and vomiting in regional anesthesia. Anesthesiology. 2003;98:530–547
  52. Roberts GW, Bekker TB, Carlsen HH, et al. Postoperative nausea and vomiting are strongly influenced by postoperative opioid use in a dose-related manner. Anesth Analg. 2005;101:1343–1348
  53. Marret E, Kurdi O, Zuffrey P, et al. Effects of nonsteroidal antiinflammatory drugs on patient-controlled analgesia morphine side effects: Meta-analysis of randomized controlled trials. Anesthesiology. 2005;102:1249–1260
  54. Ali SZ, Taguchi A, Holtmann B, et al. Effect of supplemental pre-operative fluid on postoperative nausea and vomiting. Anaesthesia. 2003;58:780–784
  55. Holte K, Klarskov B, Christensen DS, et al. Liberal versus restrictive fluid administration to improve recovery after laparoscopic cholecystectomy: A randomized, double-blind study. Ann Surg. 2004;240:892–899
  56. Kazemi-Kjellberg F, Henzi I, Tramèr MR. Treatment of established postoperative nausea and vomiting: A quantitative systematic review. BMC Anesthesiol. 2001;1:2
  57. Tramèr MR, Moore RA, Reynolds , et al. A quantitative systematic review of ondansetron in treatment of established postoperative nausea and vomiting. BMJ. 1997;314:1088–1092
  58. Moser JD, Caldwell JB, Rhule FJ. No more than necessary: Safety and efficacy of low-dose promethazine. Ann Pharmachother. 2006;40:45–48
  59. Kovac Al, O’Connor TA, Pearman MH, et al. Efficacy of repeat intravenous dosing of ondansetron in controlling postoperative nausea and vomiting: A randomized, double-blind, placebo controlled multicenter trial. J Clin Anesth. 1999;11:453–459
  60. Habib AS, Gan TJ. The effectiveness of rescue antiemetics after failure of prophylaxis with ondansetron or droperidol: a preliminary report. J Clin Anesth. 2005;17:62–65
  61. American Society of PeriAnesthesia Nurses. Evidence-based clinical practice guideline for the prevention and/or management of PONV/PDNV. J PeriAnesth Nurs. 2006;21:230–250
  62. Carroll NV, Miederhoff P, Cox FM, Hirsch JD. Postoperative nausea and vomiting after discharge from outpatient surgery centers. Anesth Analg. 1995;80:903–909
  63. Gan TJ. Postoperative nausea and vomiting: Can it be eliminated?. JAMA. 2002;13:1233–1236
  64. Gupta A, Wu CL, Elkassabany N, et al. Does the routine prophylactic use of antiemetics affect the incidence of postdischarge nausea and vomiting following ambulatory surgery?. Anesthesiology. 2003;99:488–495
  65. Gan TJ, Franiak R, Reeves J. Ondansetron orally disintegrating tablet versus placebo for the prevention of postdischarge nausea and vomiting after ambulatory surgery. Anesth Analg. 2002;94:1199–1200

PII: S1089-9472(06)00385-6

doi: 10.1016/j.jopan.2006.09.004

Journal of PeriAnesthesia Nursing
Volume 21, Issue 6 , Pages 385-397 , December 2006

Article Tools

* Image Usage & Resolution